Quanterix announces launch of new SR-Plex benchtop instrument for high sensitivity biomarker analysis

Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same way that the fully automated HD-1 Analyzer offers detection and measurement of biomarkers with unprecedented sensitivity, the SR-Plex will use single molecule measurements to assess previously undetectable proteins and can significantly reduce sample volume requirements when compared to alternative approaches, all in a benchtop format that can be easily integrated with existing automation platforms. The new platform will also be capable of measuring nucleic acids with ultra-sensitivity, without utilizing polymerase chain reaction (PCR). The first unveiling of the SR-Plex will happen today at the Next Generation Dx Summit in Washington, D.C.

“We are delivering platforms at the intersection of the digital health revolution and life science research. From high-throughput studies with our HD-1 Analyzer to the potential for blood-based, point-of-care tools, the unrivaled sensitivity of the Simoa technology helps pharma, academia and other research labs look at the most important biological information in life,” said Kevin Hrusovsky, Executive Chairman and Chief Executive Officer at Quanterix. “In addition to a smaller instrument footprint, the SR-Plex has been optimized for increased multiplexing capabilities, making it an easy to use and economical option for high sensitivity biomarker analysis, whether proteins or nucleic acids.”

The SR-Plex will be part of a complete solution, including a menu of more than 70 ultra-sensitive protein detection assays, as well as a new series of multiplex assays for critical biomarkers, including the first six-plex Simoa assay for quantitative measurement of elusive inflammatory biomarkers in the blood. As illustrated in recent publications, Simoa technology also enables measurement of ultra-sensitive nucleic acid levels, including miRNA, without utilizing PCR methodologies.

“We are particularly excited that the SR-Plex has the potential to lead to advances in the application of circulating biomarkers, especially for cancer detection and treatment. Despite recent innovations in genomic and proteomic technologies, there has been little advancement in the development of tests for immunological biomarkers,” continued Hrusovsky. “Simoa’s multiplexing capabilities and digital sensitivity provides, for the first time, the ability to measure economically circulating clinically relevant concentrations of immunological mediators, exosomes and miRNA in a single benchtop instrument.”

More than 145 studies using the Simoa technology have been published in peer-reviewed journals. This research spans several therapeutic areas such as oncology, neurology, cardiology, inflammation and infectious disease and has shown that Simoa has the potential to detect biomarkers in the subclinical state, which is valuable in the monitoring of neurodegeneration in diseases like Alzheimer’s and multiple sclerosis.

Myriad RBM, Inc., the world’s leading multiplexed immunoassay testing laboratory, will begin using the SR-Plex as part of an early-access program: “We’ve previously worked with the HD-1 Analyzer and have been consistently impressed with the flexibility of the Simoa technology and the depth that this approach provides. It allows us to detect biomarkers we couldn’t previously see with other approaches. Now, as a benchtop instrument that offers multiplexing capabilities, we can optimize our in-house laboratory robotics and liquid handlers to gain significant economies of scale, including sample preservation and throughput, which helps with our bottom line costs,” said Ralph McDade, Ph.D., President at Myriad.

The SR-Plex benchtop instrument will be on display for the first time at the Next Generation Dx Summit in Washington, D.C., August 15-17, 2017. On August 15 at 1:00 p.m. ET, Kevin Hrusovsky will lead a luncheon presentation titled “Convergence of Next Generation Digital Health and Biomarker Technologies is Enabling a Transformation to Asymptomatic Medicine and Precision Health”. Mr. Hrusovsky will also join leaders from bioMérieux and Novarum to participate in a keynote Technology Panel on August 16 at 12:15 p.m. ET titled “Disruptive Technologies in Lab Medicine”.

Quanterix will initiate an early-access program for the SR-Plex beginning in the fourth quarter of 2017 and expects full availability of the product in the first quarter of 2018. The SR-Plex is for research use only and not for use in diagnostic procedures.